Jack Allen
Stock Analyst at Baird
(0.70)
# 3,810
Out of 4,843 analysts
44
Total ratings
31.43%
Success rate
-22.21%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jack Allen
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| FATE Fate Therapeutics | Maintains: Neutral | $5 → $4 | $1.21 | +230.58% | 2 | May 14, 2025 | |
| ALLO Allogene Therapeutics | Maintains: Outperform | $12 → $9 | $1.17 | +669.23% | 3 | May 14, 2025 | |
| CARM Carisma Therapeutics | Downgrades: Neutral | $10 → $1 | $0.19 | +424.66% | 3 | Dec 12, 2024 | |
| INKT MiNK Therapeutics | Maintains: Outperform | $80 → $40 | $7.03 | +468.99% | 2 | Nov 15, 2024 | |
| VOR Vor Biopharma | Maintains: Outperform | $22 → $14 | $0.20 | +6,903.50% | 3 | Nov 8, 2024 | |
| ACLX Arcellx | Maintains: Outperform | $77 → $106 | $62.06 | +70.80% | 5 | Nov 6, 2024 | |
| NTLA Intellia Therapeutics | Maintains: Neutral | $24 → $18 | $6.87 | +162.01% | 2 | Oct 25, 2024 | |
| TIL Instil Bio | Reiterates: Outperform | $180 | $26.95 | +567.90% | 9 | Sep 16, 2024 | |
| BLUE bluebird bio | Maintains: Outperform | $140 → $120 | $4.97 | +2,314.49% | 3 | Aug 15, 2024 | |
| MREO Mereo BioPharma Group | Initiates: Outperform | $8 | $2.15 | +272.09% | 1 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $46 → $52 | $36.29 | +43.29% | 2 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $84 | $36.50 | +130.14% | 1 | Oct 31, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $6 → $8 | $2.71 | +195.20% | 4 | Aug 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $5 | $0.66 | +652.22% | 1 | Nov 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $1.46 | - | 2 | May 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $6 → $9 | $2.74 | +228.47% | 1 | Oct 7, 2021 |
Fate Therapeutics
May 14, 2025
Maintains: Neutral
Price Target: $5 → $4
Current: $1.21
Upside: +230.58%
Allogene Therapeutics
May 14, 2025
Maintains: Outperform
Price Target: $12 → $9
Current: $1.17
Upside: +669.23%
Carisma Therapeutics
Dec 12, 2024
Downgrades: Neutral
Price Target: $10 → $1
Current: $0.19
Upside: +424.66%
MiNK Therapeutics
Nov 15, 2024
Maintains: Outperform
Price Target: $80 → $40
Current: $7.03
Upside: +468.99%
Vor Biopharma
Nov 8, 2024
Maintains: Outperform
Price Target: $22 → $14
Current: $0.20
Upside: +6,903.50%
Arcellx
Nov 6, 2024
Maintains: Outperform
Price Target: $77 → $106
Current: $62.06
Upside: +70.80%
Intellia Therapeutics
Oct 25, 2024
Maintains: Neutral
Price Target: $24 → $18
Current: $6.87
Upside: +162.01%
Instil Bio
Sep 16, 2024
Reiterates: Outperform
Price Target: $180
Current: $26.95
Upside: +567.90%
bluebird bio
Aug 15, 2024
Maintains: Outperform
Price Target: $140 → $120
Current: $4.97
Upside: +2,314.49%
Mereo BioPharma Group
Jun 13, 2024
Initiates: Outperform
Price Target: $8
Current: $2.15
Upside: +272.09%
May 9, 2024
Maintains: Neutral
Price Target: $46 → $52
Current: $36.29
Upside: +43.29%
Oct 31, 2023
Initiates: Outperform
Price Target: $84
Current: $36.50
Upside: +130.14%
Aug 15, 2023
Maintains: Outperform
Price Target: $6 → $8
Current: $2.71
Upside: +195.20%
Nov 2, 2022
Initiates: Outperform
Price Target: $5
Current: $0.66
Upside: +652.22%
May 18, 2022
Upgrades: Outperform
Price Target: n/a
Current: $1.46
Upside: -
Oct 7, 2021
Upgrades: Outperform
Price Target: $6 → $9
Current: $2.74
Upside: +228.47%